UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No.)*

Akoya Biosciences, Inc.
(Name of Issuer)
Common Stock, par value \$0.00001 per share
(Title of Class of Securities)
00974Н104
(CUSIP Number)
December 31, 2023
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
⊠ Rule 13d-1(c)
☐ Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act

any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 00974H104	SCHEDULE 13G	Page 2 of 10 Pages
---------------------	--------------	--------------------

1	NAME OF REPORTING PERSONS Blue Water Life Science Advisors, LP			
2	CHECK THE API (a) □ (b) □	PROPRIA	TE BOX IF A MEMBER OF A GROUP	
3	SEC USE ONLY			
4	CITIZENSHIP OF Delaware	R PLACE	OF ORGANIZATION	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER 0	
		6	SHARED VOTING POWER 4,697,785	
		7	SOLE DISPOSITIVE POWER 0	
		8	SHARED DISPOSITIVE POWER 4,697,785	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,697,785			
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES □			
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.56%			
12	TYPE OF REPORTING PERSON IA			

CUSIP No. 00974H104	SCHEDULE 13G	Page 3 of 10 Pages
---------------------	--------------	--------------------

1	NAME OF REPORTING PERSONS			
_	Blue Water Life Science Master Fund, Ltd.			
2		PROPRIA	TE BOX IF A MEMBER OF A GROUP	
2	(a) □ (b) □			
_	SEC USE ONLY			
3				
	CITIZENSHIP OI	R PLACE	OF ORGANIZATION	
4	Cayman Islands			
	<u> </u>	_	SOLE VOTING POWER	
		5	0	
	MBER OF SHARES	6	SHARED VOTING POWER	
BEN	BENEFICIALLY OWNED BY		4,697,785	
	EACH		SOLE DISPOSITIVE POWER	
REPORTING PERSON		7	0	
	WITH		SHARED DISPOSITIVE POWER	
		8		
4,697,785				
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9			BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	4,697,785			
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES □			
10				
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
11	9.56%			
	TYPE OF REPOR	RTING PE	RSON	
12	00			

CUSIP No. 00974H104	SCHEDULE 13G	Page 4 of 10 Pages
---------------------	--------------	--------------------

1	NAME OF REPO	RTING PE	ERSONS	
1	Nathaniel T. Cornell			
CHECK THE A! (a) □		PROPRIA	TE BOX IF A MEMBER OF A GROUP	
_	(b) 🗆			
3	SEC USE ONLY			
4	CITIZENSHIP OF	R PLACE	OF ORGANIZATION	
۲	United States of A	merica		
		5	SOLE VOTING POWER	
N II 1	MDED OF	3	0	
S	MBER OF HARES	-	SHARED VOTING POWER	
	EFICIALLY VNED BY	6	4,697,785	
	EACH	_	SOLE DISPOSITIVE POWER	
REPORTING PERSON		7	0	
	WITH		SHARED DISPOSITIVE POWER	
		8	4,697,785	
9	AGGREGATE AN	MOUNT B	ENEFICIALLY OWNED BY EACH REPORTING PERSON	
9	4,697,785			
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES □			
10				
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
11	9.56%			
10	TYPE OF REPORTING PERSON			
12	IN			

	1				
1	NAME OF REPORTING PERSONS				
1	Blue Water Life	Blue Water Life Science, LP			
			ATE BOX IF A MEMBER OF A GROUP		
2	(a) □	11101111			
	(b) 🗆				
	SEC USE ONLY	SEC USE ONLY			
3					
	CITIZENSHIP O	R PLACE	OF ORGANIZATION		
4	D 1				
	Delaware	I	Tank B Marrie Bower		
		5	SOLE VOTING POWER		
	7 CD CD	3	0		
	JMBER OF SHARES		SHARED VOTING POWER		
BEN	IEFICIALLY	LLY 6 BY 7	4 (07 705		
O	WNED BY EACH		4,697,785		
RE	EPORTING		SOLE DISPOSITIVE POWER		
]	PERSON		0		
	WITH		SHARED DISPOSITIVE POWER		
		8	4,697,785		
_	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
9	4,697,785				
	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				
10	CHECK II THE AGGREGATE ANIOUNT IN ROW (7) EACLODES CERTAIN SHARES				
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
11	9.56%				
	TYPE OF REPOR	RTING PE	ERSON		
12	DNI				
	PN				

CUSI	P No. 00974H104	SCHEDULE 13G	Page 6 of 10 Pages
Item 1.	(a) Name of Issuer		
	Akoya Biosciences, Inc.		
Item 1.	(b) Address of Issuer's Principal Executive O	offices	
	100 Campus Drive, 6th Floor Marlborough,		
	Massachusetts 01752		
Item 2.	(a) Names of Person Filing:		
	(i) Blue Water Life Science Advisors, LP		
	(ii) Blue Water Life Science Master Fund, Ltd.		
	(iii) Nathaniel T. Cornell		
	(iv) Blue Water Life Science, LP		
Item 2.	(b) Address of Principal Business Office:		
	(i) 80 E. Sir Francis Drake Blvd. Suite 4A Larkspur, California 94939		
	(ii) 4th PL, Harbour Place 103 S Church St Grand Cayman, Cayman Islands KYI-100	2	
	(iii) 80 E. Sir Francis Drake Blvd. Suite 4A Larkspur, California 94939		
	(iv) 80 E. Sir Francis Drake Blvd. Suite 4A Larkspur, California 94939		
Item 2.	(c) Citizenship:		
	(i) Delaware		
	(ii) Cayman Islands		
	(iii) United States of America		
	(iv) Delaware		
Item 2.	(d) Title of Class of Securities		
	Common Stock, par value \$0.00001 per share	re (the "Common Stock")	
Item 2.	(e) CUSIP No.:		
	00974H104		
CUSI	P No. 00974H104	SCHEDULE 13G	Page 7 of 10 Pages
		L	
Item 3.	If this statement is filed pursuant to §§240.13	3d-1(b) or 240.13d-2(b) or (c), check whether the per	son filing is a:

(c) \square Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(f) □ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g) □ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(d) \square Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

CUSIP No. 00974H104	SCHEDULE 13G	Page 8 of 10 Pages
(k) ☐ A group, in accordance with §24 specify the type of institution:	0.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accord	ance with §240.13d-1(b)(1)(ii)(J), please
(j) \(\subseteq \) A non-U.S. institution in accorda		
(i) A church plan that is excluded fr (15 U.S.C. 80a-3);	om the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940

(h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

Item 4. Ownership

Information with respect to the Reporting Persons' ownership of the Common Stock as of December 31, 2023 is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person.

The amount beneficially owned by each Reporting Person is determined based on 49,117,738 shares of Common Stock outstanding as of December 31, 2023, as the Issuer reported in its Form 10-K filed with the SEC on March 5, 2024.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [].

Item 6. Ownership of More Than Five Percent on Behalf of Another Person

Not Applicable.

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Not Applicable.

Item 8. Identification and Classification of Members of the Group

Not Applicable.

Item 9. Notice of Dissolution of Group

Not Applicable.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: August 28, 2024

Blue Water Life Science Advisors, LP

By: Entity and Description

By: /s/ Nathaniel T. Cornell

Nathaniel T. Cornell, Managing Member

Blue Water Life Science Master Fund, Ltd.

By: Entity and Description

By: /s/ Nathaniel T. Cornell

Nathaniel T. Cornell, Managing Member

Nathaniel T. Cornell

By: Entity and Description

By: /s/ Nathaniel T. Cornell

Nathaniel T. Cornell

Blue Water Life Science, LP

By: Entity and Description

By: /s/ Nathaniel T. Cornell

Nathaniel T. Cornell, Managing Member

CUSIP No. 00974H104 SCHEDULE 13G Page 10 of 10 Pages

Exhibit I

JOINT FILING STATEMENT

PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Dated: August 28, 2024

Blue Water Life Science Advisors, LP

By: /s/ Nathaniel T. Cornell

Nathaniel T. Cornell, Managing Member

Blue Water Life Science Master Fund, Ltd.

By: /s/ Nathaniel T. Cornell

Nathaniel T. Cornell, Managing Member

Nathaniel T. Cornell

By: /s/ Nathaniel T. Cornell

Nathaniel T. Cornell

Blue Water Life Science, LP

By: /s/ Nathaniel T. Cornell

Nathaniel T. Cornell, Managing Member